Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Triple Negative Breast Cancer
Interventions: ProAgio Dose Levels (DL) 1,2,3,4, ProAgio Dose Expansion; Drug
Lead sponsor: ProDa BioTech, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Technology-based information and coaching/support program, American Cancer Society information on breast cancer; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Atlanta, Georgia • Durham, North Carolina

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Microbiota-based Formulation RBX7455; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions: CB-10-01 (Transgenic Lymphocyte Immunization); Biological
Lead sponsor: Cosmo Bioscience; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 2 more

Conditions: Malignant Melanoma
Interventions: UV1, GM-CSF; Drug
Lead sponsor: Ultimovacs ASA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Santa Monica, California • Iowa City, Iowa • Easton, Pennsylvania + 1 more

Conditions: Breast Cancer
Interventions: Tamoxifen Citrate, Letrozole, Exemestane, Blueprint, Mammaprint; Drug · Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Duloxetine; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Early-stage Breast Cancer, Fear of Cancer Recurrence, Anxiety, Depression
Interventions: Psilocybin 25 mg, Psilocybin 5 mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Melanoma (Skin)
Interventions: Fianlimab, Cemiplimab; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Orange, California

Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer
Interventions: RPTR-168; Biological
Lead sponsor: Repertoire Immune Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • Ann Arbor, Michigan + 1 more

Conditions: Psoriasis
Interventions: Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser; Drug · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Melanoma (Skin)
Interventions: CP-675,206; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Skin Laxity
Interventions: Sofwave, Ultherapy; Device
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 35 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetic Foot Ulcer
Interventions: No intervention-retrospective study; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Diagnostic Breast Cancer Scan, Research Scan for Gradient-echo Spectroscopic Imaging (GSI); Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 25 Years to 99 Years · Female only
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma
Interventions: Best Practice, Cognitive Behavior Therapy, Electronic Health Record Review, Questionnaire Administration; Other · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Foot Ulcers, Wound Care
Interventions: AmnioClear™ Human Allograft Amniotic Membrane; Biological
Lead sponsor: Liventa Bioscience; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more

Conditions: Breast Cancer
Interventions: Ductal Lavage Fluid Collection; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Dasatinib, AZD6244; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Carcinoma
Interventions: Electronic Health Record Review, Ultrasound Microvessel Imaging; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 945 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

To Enhance Breast Cancer Survivorship of Asian Americans

RBX7455 Before Surgery for the Treatment of Operable Breast Cancer

A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

Psilocybin FCR Early-Stage Breast Cancer

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

High Intensity Ultrasound for the Treatment of Upper Inner Arm Skin Laxity

The Effect of Implementing a Limb Loss Prevention Program on Amputation Rates

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients

A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds

Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions

Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer

Personalized Treatment Selection for Metastatic Breast Cancer

3D Ultrasound Microvessel Imaging for Breast Masses

A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer